Acta Scientific Cancer Biology (ASCB) (ISSN: 2582-4473)

Review Article Volume 5 Issue 9

A Review on Systemic and New Cancer Hallmarks

Akruti Amol Ingole1, Anjali Vijay Petle2, Surbhi Balwant Dhoke3, Piyush Jagdish Balgote4, Anirban Goutam Mukherjee5 and Uddesh Ramesh Wanjari3*

1Department of Biotechnology, Priyadarshini Institute of Engineering and Technology, Nagpur, Maharashtra, India
2Department of Biochemistry, RTM Nagpur University, Nagpur, Maharashtra, India
3Department of Biochemistry, Kamla Nehru Mahavidyalaya, Nagpur, Maharashtra, India
4Molecular Biology and Genetic Engineering, RTM Nagpur University, Nagpur, Maharashtra, India
5Department of Biosciences, School of Bio-Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India

*Corresponding Author: Uddesh Ramesh Wanjari, Department of Biochemistry, Kamla Nehru Mahavidyalaya, Nagpur, Maharashtra, India.

Received: August 13, 2021; Published: August 19, 2021

Abstract

The body system is dependent on each other through communication, cancer development can be supported by the new cancer-induced pathological systemic networks (CISPN), and the entire organism is “cancerized.” The significant anomaly in the transition of epithelial cells to mesenchymal cells plays a vital role in neural crest migration. The metastatic program follows a transformed cellular communication process that, activated once, causes dispersed tumors at a distance from the original site. This review aims to provide an idea of various systemic and new hallmarks and several altered networking processes that eventually end up causing cancer.

Keywords: Cancer; Hallmarks; Inflammation; Cytokines; Tumor

References

  1. Paul D. “The systemic hallmarks of cancer”. Journal of Cancer Metastasis and Treatment 6 (2020).
  2. Zhong Z., et al. “Wnts and the hallmarks of cancer”. Cancer and Metastasis Reviews3 (2020): 625-645.
  3. Senga SS and Grose RP. “Hallmarks of cancer—the new testament”. Open Biology1 (2021): 200358.
  4. Hong WX., et al. “Intratumoral immunotherapy for early-stage solid tumors”. Clinical Cancer Research13 (2020): 3091-3099.
  5. McAllister SS and Weinberg RA. “The tumor-induced systemic environment as a critical regulator of cancer progression and metastasis”. Nature Cell Biology8 (2014): 717-727.
  6. Dudás J., et al. “Epithelial to mesenchymal transition: A mechanism that fuels cancer radio/chemoresistance”. Cells2 (2020): 428.
  7. Vincent MD. “The animal within: carcinogenesis and the clonal evolution of cancer cells are speciation events sensu stricto”. Evolution 4 (2010): 1173-1183.
  8. Gooding AJ and Schiemann WP. “Epithelial–mesenchymal transition programs and cancer stem cell phenotypes: mediators of breast cancer therapy resistance”. Molecular Cancer Research9 (2020): 1257-1270.
  9. Flanigan RC and Yonover PM. “The role of radical nephrectomy in metastatic renal cell carcinoma”. Seminar on Urology and Oncology 2 (2001): 98-102.
  10. Kaplan RN., et al. “VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche”. Nature7069 (2005): 820-827.
  11. Guo L and Guo N. “Exosomes: Potent regulators of tumor malignancy and potential bio-tools in clinical application”. Critical Reviews in Oncology/Hematology 3 (2015): 346-358.
  12. Grivennikov SI., et al. “Immunity, inflammation, and cancer”. Cell 6 (2010): 883-899.
  13. Nishida J., et al. “Epigenetic remodelling shapes inflammatory renal cancer and neutrophil-dependent metastasis”. Nature Cell Biology4 (2020): 465-475.
  14. Tisdale MJ. “Mechanisms of cancer cachexia”. Physiology Review2 (2009): 381-410.
  15. Fearon KC., et al. “Cancer cachexia: mediators, signaling, and metabolic pathways”. Cell Metabolism2 (2012): 153-166.
  16. Porporato PE. “Understanding cachexia as a cancer metabolism syndrome”. Oncogenesis2 (2016): e200.
  17. Wang F., et al. “The Warburg effect in human pancreatic cancer cells triggers cachexia in athymic mice carrying the cancer cells”. BMC Cancer1 (2018): 1-12.
  18. Chasen M., et al. “Immunomodulatory agents for the treatment of cachexia”. Current Opinion in Supportive and Palliative Care 4 (2014): 328-333.
  19. Falanga A., et al. “Mechanisms and risk factors of thrombosis in cancer”. Critical Reviews in Oncology/Hematology 118 (2017): 79-83.
  20. Versteeg HH., et al. “Inhibition of tissue factor signaling suppresses tumor growth”. Blood1 (2008): 190-199.
  21. Jiang SH., et al. “Systemic Regulation of Cancer Development by Neuro-Endocrine-Immune Signaling Network at Multiple Levels”. Frontiers in Cell and Developmental Biology 8 (2020): 1056.
  22. Braun TP., et al. “Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitary-adrenal axis”. Journal of Experimental Medicine 12 (2011): 2449-2463.
  23. Yehya AHS., et al. “Angiogenesis: managing the culprits behind tumorigenesis and metastasis”. Medicina 1 (2018): 8.
  24. Wang L., et al. “Fbxw11 promotes the proliferation of lymphocytic leukemia cells through the concomitant activation of NF-κB and β-catenin/TCF signaling pathways”. Cell Death and Disease4 (2018): 1-12.
  25. de Souza CF., et al. “A distinct DNA methylation shift in a subset of glioma CpG island methylator phenotypes during tumor recurrence”. Cell Reports2 (2018): 637-651.
  26. Takahashi K and Yamanaka S. “Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors”. Cell 126 (2006): 663-676.
  27. , et al. “Direct reprogramming by oncogenic Ras and Myc”. Proceedings of the National Academy of Sciences of the United States of America 110.10 (2013): 3937-3942.
  28. Müller J., et al. “Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma”. Nature Communication 5 (2014): 5712.
  29. Mu P., et al. “SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer”. Science 6320 (2017): 84-88.
  30. Li Y., et al. “Compression-induced dedifferentiation of adipocytes promotes tumor progression”. Science Advances 4 (2020): eaax5611.
  31. Halim S., et al. “Analysis of cell proliferation and tissue remodelling uncovers a KLF4 activity score associated with poor prognosis in colorectal cancer”. British Journal of Cancer7 (2018): 855-863.
  32. Strickland S., et al. “The induction of differentiation in teratocarcinoma stem cells by retinoic acid”. Cell 2 (1978): 393-403.
  33. Augimeri G., et al. “Natural and synthetic PPARγ ligands in tumor microenvironment: a new potential strategy against breast cancer”. International Journal of Molecular Sciences24 (2020): 9721.
  34. Chen J., et al. “H3K9 methylation is a barrier during somatic cell reprogramming into iPSCs”. Nature Genetics1 (2013): 34-42.
  35. Giorda R. “Principles of epigenetics and DNA methylation”. In Developmental Human Behavioral Epigenetics (2020): 3-26.
  36. Zhang W., et al. “Global DNA hypomethylation in epithelial ovarian cancer: passive demethylation and association with genomic instability”. Cancers3 (2020): 764.
  37. Jankowska S., et al. “Molecular classification of glioblastoma based on immunohistochemical expression of EGFR, PDGFRA, NF1, IDH1, p53 and PTEN proteins”. Polish Journal of Pathology1 (2021): 1-10.
  38. Kim KH and Roberts CW. “Targeting EZH2 in cancer”. Nature Medicine2 (2016): 128-134.
  39. Sun J., et al. “N-terminal truncated carboxypeptidase E represses E-cadherin expression in lung cancer by stabilizing the Snail-HDAC complex”. American Journal of Cancer Research3 (2020): 925.
  40. Jain SU., et al. “Histone H3. 3 G34 mutations promote aberrant PRC2 activity and drive tumor progression”. Proceedings of the National Academy of Sciences44 (2020): 27354-27364.
  41. Sasagawa T., et al. “Production of an anti-angiogenic factor sFLT1 is suppressed via promoter hypermethylation of FLT1 gene in choriocarcinoma cells”. BMC Cancer1 (2020): 112.
  42. Shabgah AG., et al. “Chemokine CXCL14; a double-edged sword in cancer development”. International Immunopharmacology 97 (2021): 107681.
  43. Yoshihama S., et al. “NLRC5/MHC class I transactivator is a target for immune evasion in cancer”. Proceedings of the National Academy of Sciences of the United States of America 21 (2016): 5999-6004.
  44. Cirone M. “Cancer cells dysregulate PI3K/AKT/mTOR pathway activation to ensure their survival and proliferation: mimicking them is a smart strategy of gammaherpesviruses”. Critical Reviews in Biochemistry and Molecular Biology (2021): 1-10.
  45. Nishida J., et al. “Epigenetic remodelling shapes inflammatory renal cancer and neutrophil-dependent metastasis”. Nature Cell Biology4 (2020): 465-475.
  46. Hatakeyama M. “Helicobacter pylori CagA and gastric cancer: a paradigm for hit-and-run carcinogenesis”. Cell Host Microbe3 (2014): 306-316.
  47. Partecke LI., et al. “Chronic stress increases experimental pancreatic cancer growth, reduces survival and can be antagonised by beta-adrenergic receptor blockade”. Pancreatology3 (2016): 423-33.
  48. Kamiya A., et al. “Genetic manipulation of autonomic nerve fiber innervation and activity and its effect on breast cancer progression”. Nature Neuroscience8 (2019): 1289-1305.
  49. Mukherjee AG., et al. “A Review on The Usefulness of Various Eukaryotic Pigments and Metabolites in Cancer Treatment”. WJPR10 (2020): 587-611.
  50. Mukherjee AG., et al. “A Review on the Present and Future Aspects of Various Prokaryotic Pigments and Metabolites Demonstrating Anti-Cancerous Properties”. International Journal of Engineering Research and Technology7 (2020): 1262-1266.
  51. Ingole AA., et al. “A Review on Carcinogenic Heavy Metals”. International Journal of Engineering Research and Technology3 (2021): 403-411.
  52. Mukherjee AG and Wanjari U. “A Short Review on Various Aspects of Gene Sequencing and Metagenomics to Study Human Gut Microbiome”. International Research Journal of Engineering and Technology7 (2020): 1280-1284.
  53. Mukherjee AG., et al. “The CRISPR-Cas System as a Technology to Redefine Industrial Biotechnology”. Acta Scientific Microbiology6 (2021): 45-52.

Citation

Citation: Ingole, A.A., Petle, A.V., Dhoke, S.B., Balgote, P.J., Mukherjee, A.G., and Wanjari, U.R. “A Review on Systemic and New Cancer Hallmarks”. Acta Scientific Cancer Biology 5.9 (2021): 18-25.

Copyright

Copyright: © 2021 Uddesh Ramesh Wanjari., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate35%
Acceptance to publication20-30 days
Impact Factor1.018

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is December 05, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US